Sulfadoxine pyrimethamine + Amodiaquine
ApprovedSmall molecule
Sulfadoxine pyrimethamine + Amodiaquine is one of 21 small molecule programs targeting Malaria. It is currently in Approved.
1
Indications
2
Total Trials
2
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
479 competitors in Malaria
#DrugCompanyPhaseTrials
1Sulfadoxine pyrimethamine + Amodiaquine
SStanford University
Approved
Biltricide
BayerPreclinical
Stelara
Johnson & JohnsonPreclinical
Hydroxychloroquine Sulfate
NovartisPreclinical
Iron
WWatson Pharmaceuticals
Preclinical
IV LBH589
NovartisPreclinical
Mefloquine Plus Artesunate
Medicines for Malaria VenturePreclinical
IV Ceftriaxone
RRESnTEC, Institute of Research
Preclinical
RTS,S/AS01E
GSKPreclinical
Malarone
Medicines for Malaria VenturePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SStanford University